{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:27:59Z","timestamp":1789504079658,"version":"build-2803163510"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>A ready-to-use liquid formulation of abobotulinumtoxinA (aboBoNT-A solution) has been developed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The aim of this study was to assess the long-term efficacy and safety of aboBoNT-A solution for the treatment of glabellar lines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a multicenter, multinational, Phase III study (NCT02493946), with randomized double-blind placebo-controlled (DBPC; 2:1 aboBoNT-A solution 50 U\/placebo) and open-label (4 cycles aboBoNT-A solution) periods; additional patients were recruited into the open-label period. Patients were 18 to 65 years old, BoNT-na\u00efve, and dissatisfied\/very dissatisfied with moderate\/severe glabellar lines at maximum frown. Investigator\u2019s live assessment (primary endpoint)\/subject\u2019s self-assessment of glabellar line severity at maximum frown, patient satisfaction with glabellar line appearance, and FACE-Q patient-reported scales (facial appearance overall, psychological well-being, aging) were assessed. Adverse events were monitored. Analyses were performed on DBPC and long-term analysis (LTA; all patients receiving \u22651 aboBoNT-A solution injection) populations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Responder rates for the investigator\u2019s live assessment, the subject\u2019s self-assessment, and patient satisfaction were consistent at Day 29 postinjection across repeat LTA cycles (82.2%-87.8%, 62.8%-80.6%, and 72.2%-87.8%, respectively), with statistically significantly higher responder rates vs placebo (DBPC cycle: 81.6% vs 0.8%, 68.1% vs 2.3%, and 83.1% vs 5.7%, respectively; all P &amp;lt; 0.0001). Consistent improvements on FACE-Q scales occurred with repeat cycles (DBPC cycle: aboBoNT-A solution vs placebo, P &amp;lt; 0.0001). No new or unexpected adverse events, or neutralizing antibodies, were observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These results support the long-term efficacy and safety of aboBoNT-A solution, and its superiority over placebo, for treatment of glabellar lines in adults.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Level of Evidence: 1<\/jats:title>\n                  <jats:p\/>\n               <\/jats:sec>","DOI":"10.1093\/asj\/sjab329","type":"journal-article","created":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T10:59:50Z","timestamp":1630580390000},"page":"301-313","source":"Crossref","is-referenced-by-count":19,"title":["Long-term Efficacy and Safety of Liquid AbobotulinumtoxinA Formulation for Moderate-to-Severe Glabellar Lines: A Phase III, Double-Blind, Randomized, Placebo-Controlled and Open-Label Study"],"prefix":"10.1093","volume":"42","author":[{"given":"Philippe","family":"Kestemont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Hilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill","family":"Andriopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Prygova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Volteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ascher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"key":"2024082909570451100_CIT0001","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/CIA.S9338","article-title":"Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction","volume":"5","author":"De Boulle","year":"2010","journal-title":"Clin Interv Aging."},{"key":"2024082909570451100_CIT0002","doi-asserted-by":"crossref","first-page":"518e","DOI":"10.1097\/01.prs.0000475758.63709.23","article-title":"Global aesthetics consensus: botulinum toxin type A\u2014evidence-based review, emerging concepts, and consensus recommendations for aesthetic use, including updates on complications","volume":"137","author":"Sundaram","year":"2016","journal-title":"Plast Reconstr Surg."},{"issue":"3","key":"2024082909570451100_CIT0003","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cps.2016.03.003","article-title":"Overview of botulinum toxins for aesthetic uses","volume":"43","author":"Gart","year":"2016","journal-title":"Clin Plast Surg."},{"key":"2024082909570451100_CIT0004","author":"Allergan\u201a Inc","year":"2018"},{"key":"2024082909570451100_CIT0005","author":"Merz Pharmaceuticals\u201a LLC","year":"2018"},{"key":"2024082909570451100_CIT0006","author":"Ipsen Biopharm Ltd","year":"2020"},{"key":"2024082909570451100_CIT0007","author":"Electronic Medicines Compendium","year":"2019"},{"key":"2024082909570451100_CIT0008","author":"Electronic Medicines Compendium","year":"2020"},{"issue":"2","key":"2024082909570451100_CIT0009","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/asj\/sjw272","article-title":"Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial","volume":"38","author":"Ascher","year":"2018","journal-title":"Aesthet Surg J."},{"issue":"1","key":"2024082909570451100_CIT0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/asj\/sjz003","article-title":"Liquid formulation of abobotulinumtoxinA: a 6-month, phase 3, double-blind, randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines","volume":"40","author":"Ascher","year":"2020","journal-title":"Aesthet Surg J."},{"issue":"9","key":"2024082909570451100_CIT0011","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/asj\/sjz248","article-title":"Significantly increased patient satisfaction following liquid formulation abobotulinumtoxinA treatment in glabellar lines: FACE-Q outcomes from a phase 3 clinical trial","volume":"40","author":"Ascher","year":"2020","journal-title":"Aesthet Surg J."},{"issue":"2","key":"2024082909570451100_CIT0012","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1046\/j.1365-2133.2003.05436.x","article-title":"Reproducibility of a four-point clinical severity score for glabellar frown lines","volume":"149","author":"Honeck","year":"2003","journal-title":"Br J Dermatol."},{"issue":"2","key":"2024082909570451100_CIT0013","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cps.2012.12.001","article-title":"Development and psychometric evaluation of the FACE-Q satisfaction with appearance scale: a new patient-reported outcome instrument for facial aesthetics patients","volume":"40","author":"Pusic","year":"2013","journal-title":"Clin Plast Surg."},{"issue":"2","key":"2024082909570451100_CIT0014","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/PRS.0000000000000895","article-title":"FACE-Q scales for health-related quality of life, early life impact, satisfaction with outcomes, and decision to have treatment: development and validation","volume":"135","author":"Klassen","year":"2015","journal-title":"Plast Reconstr Surg."},{"issue":"8","key":"2024082909570451100_CIT0015","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1177\/1090820X13510170","article-title":"Development and psychometric evaluation of the FACE-Q aging appraisal scale and patient-perceived age visual analog scale","volume":"33","author":"Panchapakesan","year":"2013","journal-title":"Aesthet Surg J."},{"key":"2024082909570451100_CIT0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03475.x","article-title":"Treatment of glabellar lines with botulinum toxin type A (Speywood Unit): a clinical overview","volume":"24","author":"Rzany","year":"2010","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"2","key":"2024082909570451100_CIT0017","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jaad.2003.11.084","article-title":"A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines","volume":"51","author":"Ascher","year":"2004","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"2024082909570451100_CIT0018","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.asj.2005.05.004","article-title":"Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection","volume":"25","author":"Ascher","year":"2005","journal-title":"Aesthet Surg J."},{"issue":"12","key":"2024082909570451100_CIT0019","first-page":"E56","article-title":"Onset and duration of abobotulinumtoxinA for aesthetic use in the upper face: a systematic literature review","volume":"13","author":"Nestor","year":"2020","journal-title":"J Clin Aesthet Dermatol."},{"issue":"1","key":"2024082909570451100_CIT0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/DSS.0000000000002013","article-title":"Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines","volume":"46","author":"Monheit","year":"2020","journal-title":"Dermatol Surg."},{"issue":"suppl_1","key":"2024082909570451100_CIT0021","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1093\/asj\/sjx010","article-title":"Safety and patient satisfaction of abobotulinumtoxinA for aesthetic use: a systematic review","volume":"37","author":"Cohen","year":"2017","journal-title":"Aesthet Surg J."},{"issue":"2","key":"2024082909570451100_CIT0022","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/DSS.0000000000001277","article-title":"Botulinum toxin in aesthetic medicine: myths and realities","volume":"44","author":"Dover","year":"2018","journal-title":"Dermatol Surg."},{"issue":"1","key":"2024082909570451100_CIT0023","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijwd.2018.08.001","article-title":"Beyond the physician\u2019s perspective: a review of patient-reported outcomes in dermatologic surgery and cosmetic dermatology","volume":"5","author":"Mori","year":"2019","journal-title":"Int J Womens Dermatol."}],"container-title":["Aesthetic Surgery Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/asj\/advance-article-pdf\/doi\/10.1093\/asj\/sjab329\/40731760\/sjab329.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/42\/3\/301\/58962342\/sjab329.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/42\/3\/301\/58962342\/sjab329.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T12:24:09Z","timestamp":1724934249000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/asj\/article\/42\/3\/301\/6362548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,2]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,9,2]]},"published-print":{"date-parts":[[2022,2,15]]}},"URL":"https:\/\/doi.org\/10.1093\/asj\/sjab329","relation":{},"ISSN":["1090-820X","1527-330X"],"issn-type":[{"value":"1090-820X","type":"print"},{"value":"1527-330X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2021,9,2]]}}}